TMO
Thermo Fisher Scientific (NYSE: TMO) posted strong revenue growth of 6% to $11.
Article Summary
BUY- Thermo Fisher Scientific (NYSE: TMO) posted strong revenue growth of 6% to $11.01 billion, with operating margins expanding to 21.8% and EPS rising 6%.
- Thermo Fisher Scientific raised full-year revenue guidance to $47.3-48.1 billion, reflecting 6%-8% growth over 2025, and increased its dividend by 10% after repurchasing $3 billion in shares and raising the dividend 10%.
- Life Sciences Solutions revenue increased 13% with 1% organic growth, while Analytical Instruments revenue declined 2% due to lower academic and government demand.
- The company completed the acquisition of Clario, adding $30 million in revenue and $0.01 to adjusted EPS, while launching Cryo-TEM and TSQ Certis mass spectrometer technologies.
- Guidance for 2026 was raised due to stronger-than-expected revenue and EPS growth, though investors remain cautious due to macro pressures.
- TMO faces modest inflationary pressures from conflict in the Middle East and tariffs, which could pressure margins.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 5.4% | 25% | 35.0 ptsBelow Screener (5.4%) - Weak growth |
| EPS Growth Next 5Y ? | 9.5% | 25% | 20.0 ptsWeak (9.5%) - Low expectations |
| Target Price Upside ? | 35.7% | 20% | 85.0 ptsLarge Upside (35.7%) - Target: $635.87 vs Current: $468.50 |
| Gross Margin % ? | 39.2% | 15% | 60.0 ptsSolid (39.2%) - Decent margins |
| Drawdown from 52-Wk High ? | -27.3% | 15% | 80.0 ptsSolid Dip (-27.3%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About TMO
- Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.
- It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
- The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases.
- Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.
- The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings.
- Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research.
- Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.